Please assess the completion status of the following clinical trial:

Trial Title: Adaptive COVID-19 Treatment Trial (ACTT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted to a hospital with symptoms suggestive of COVID-19 infection.~2. Subject (or legally authorized representative) provides informed consent prior to initiation of any study procedures.~3. Subject (or legally authorized representative) understands and agrees to comply with planned study procedures.~4. Male or non-pregnant female adult \> / = 18 years of age at time of enrollment.~5. Has laboratory-confirmed SARS-CoV-2 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay in any specimen, as documented by either or the following:~   1. PCR positive in sample collected \< 72 hours prior to randomization; OR~      Exclusion Criteria:~  2. PCR positive in sample collected \>/= 72 hours prior to randomization, documented inability to obtain a repeat sample (e.g. due to lack of testing supplies, limited testing capacity, results taking \>24 hours, etc.) AND progressive disease suggestive of ongoing SARS-CoV-2 infection.~6. Illness of any duration, and at least one of the following:~   1. Radiographic infiltrates by imaging (chest x-ray, CT scan, etc.), OR~  2. SpO2 \< / = 94% on room air, OR~  3. Requiring supplemental oxygen, OR~  4. Requiring mechanical ventilation.~7. Women of childbearing potential must agree to either abstinence or use at least one primary form of contraception not including hormonal contraception from the time of screening through Day 29.~8. Agrees to not participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 through Day 29.~Exclusion Criteria:~1. Alanine Transaminase (ALT) or Aspartate Transaminase (AST) \> 5 times the upper limit of normal.~2. Estimated glomerular filtration rate (eGFR) \< 30 ml/min (including patients receiving hemodialysis or hemofiltration).~3. Pregnancy or breast feeding.~4. Anticipated discharge from the hospital or transfer to another hospital which is not a study site within 72 hours.~5. Allergy to any study medication.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 200 mg of Remdesivir placebo administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir placebo while hospitalized for up to a 10 days total course. n=286.
- Remdesivir (Type: EXPERIMENTAL): 200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10 days total course. n=286.

Based on this trial design, predict the completion outcome and termination type (if applicable).